scholarly article | Q13442814 |
P819 | ADS bibcode | 2016PLoSO..1146465M |
P356 | DOI | 10.1371/JOURNAL.PONE.0146465 |
P932 | PMC publication ID | 4749572 |
P698 | PubMed publication ID | 26863139 |
P5875 | ResearchGate publication ID | 293827425 |
P50 | author | Franz König | Q40096364 |
Martin Posch | Q42321315 | ||
P2093 | author name string | Thomas Jaki | |
Dominic Magirr | |||
P2860 | cites work | Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency | Q26824359 |
A practical simulation method to calculate sample size of group sequential trials for time-to-event data under exponential and Weibull distribution | Q28483447 | ||
Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections | Q30669416 | ||
The reassessment of trial perspectives from interim data--a critical view | Q31010971 | ||
Adaptive trial design: a general methodology for censored time to event data | Q33398428 | ||
Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints | Q35226583 | ||
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study | Q36770191 | ||
Adaptive designs for confirmatory clinical trials | Q37389417 | ||
Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls. | Q38380750 | ||
Adaptive seamless designs with interim treatment selection: a case study in oncology | Q41498564 | ||
An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints | Q44262116 | ||
A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information | Q45374094 | ||
Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology | Q46054107 | ||
A conditional error function approach for subgroup selection in adaptive clinical trials | Q46406244 | ||
Mid-course sample size modification in clinical trials based on the observed treatment effect | Q47172162 | ||
Adaptive sample size calculations in group sequential trials | Q47213254 | ||
Flexible two-stage design with sample size reassessment for survival trials | Q47283214 | ||
Adaptive increase in sample size when interim results are promising: a practical guide with examples | Q47342519 | ||
Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections, by H. Schäfer and H.-H. Müller, Statistics in Medicine 2001; 20: 3741-3751. | Q47422901 | ||
Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: an application in multiple sclerosis | Q48152166 | ||
When is a seamless study desirable? Case studies from different pharmaceutical sponsors | Q50116411 | ||
Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint. | Q51911840 | ||
Evaluation of experiments with adaptive interim analyses. | Q52364596 | ||
Properties of proportional-hazards score tests under misspecified regression models | Q70778836 | ||
Designed extension of studies based on conditional power | Q70971455 | ||
Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches | Q74497643 | ||
Planning and analyzing adaptive group sequential survival trials | Q80261915 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | hypothesis testing | Q110783625 |
P304 | page(s) | e0146465 | |
P577 | publication date | 2016-02-10 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Sample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials | |
P478 | volume | 11 |
Q47676741 | Adaptive designs for the one-sample log-rank test. |
Q59336746 | Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency |
Q59136188 | Applicability and added value of novel methods to improve drug development in rare diseases |
Q53281780 | Bias, Operational Bias, and Generalizability in Phase II/III Trials. |
Q54941922 | Lessons learned from IDeAl - 33 recommendations from the IDeAl-net about design and analysis of small population clinical trials. |
Q47574086 | Optimized adaptive enrichment designs |
Q38630899 | Sample size adjustment designs with time-to-event outcomes: A caution |
Search more.